In lat­est blow to Eli Lil­ly, Sanofi wins FDA OK for Hu­ma­log me-too

Sanofi $SNY got the green­light from FDA to sell its me-too in­sulin prod­uct Ad­mel­og, threat­en­ing mar­ket leader Eli Lil­ly’s $LLY block­buster sales in di­a­betes.

Ad­mel­og, a short-act­ing in­sulin lispro in­jec­tion, is a fol­low-on prod­uct ap­proved through an ab­bre­vi­at­ed path­way un­der the FDA’s Fed­er­al Food, Drug, and Cos­met­ic Act. FDA Com­mis­sion­er Scott Got­tlieb is de­liv­er­ing on his promise to en­cour­age more com­pe­ti­tion in the mar­ket­place, cheer­ing the ap­proval in to­day’s state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER